The pharmacokinetics of mometasone furoate administered by dry powder inhaler following single and multiple dosing in patients with mild-to-moderate persistent asthma

M. B. Affrime, T. Kosoglou (Kenilworth, United States Of America)

Source: Annual Congress 2001 - Inhaled corticosteroids
Session: Inhaled corticosteroids
Session type: Thematic Poster Session
Number: 684
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. B. Affrime, T. Kosoglou (Kenilworth, United States Of America). The pharmacokinetics of mometasone furoate administered by dry powder inhaler following single and multiple dosing in patients with mild-to-moderate persistent asthma. Eur Respir J 2001; 16: Suppl. 31, 684

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Once-daily, evening administration of mometasone furoate dry powder inhaler improves pulmonary function in patients with mild to moderate persistent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 282s
Year: 2003

Effects of mometasone furoate dry powder inhaler administered once-daily in the evening on symptom control in mild to moderate asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 282s
Year: 2003

Assessment of the defined daily dose for mometasone furoate dry powder inhaler in persistent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 33s
Year: 2003

Once-daily versus twice-daily administration of mometasone furoate dry powder inhaler (MF-DPI) improves lung function in children with asthma previously maintained on inhaled corticosteroids (ICS)
Source: Eur Respir J 2004; 24: Suppl. 48, 164s
Year: 2004

A superior improvement in lung function in patients with moderate persistent asthma is seen with mometasone furoate 200 μg b.i.d delivered by dry powder inhaler compared with beclomethasone dipropionate 168 μg
Source: Eur Respir J 2001; 18: Suppl. 33, 96s
Year: 2001

Administration of mometasone furoate once daily in the evening is as effective as mometasone furoate administered twice daily in improving lung function in patients with mild to moderate persistent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 33s
Year: 2003

Mometasone furoate dry powder inhaler administered once-daily in the evening reduces overnight and early morning symptoms of mild to moderate asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 282s
Year: 2003

Once-daily mometasone furoate dry powder inhaler preserves lung function, reduces symptoms, and delays exacerbations in patients with COPD previously maintained on ICS
Source: Eur Respir J 2003; 22: Suppl. 45, 4s
Year: 2003

Effects of one year of treatment with mometasone furoate metered dose inhaler (MF-MDI) on growth in children with asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 378s
Year: 2004

Does health-related quality of life improve with QD and BID dosing of mometasone furoate dry-powder inhaler (MF DPI) in patients with mild to moderate persistent asthma previously using inhaled corticosteroids?
Source: Eur Respir J 2003; 22: Suppl. 45, 283s
Year: 2003

Clinical efficacy of once-daily mometasone furoate in children with persistent asthma switched from treatment with fluticasone propionate
Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Year: 2011

Comparative efficacy and safety of mometasone furoate dry powder inhaler and budesonide Turbuhaler(R)
Source: Eur Respir J 2001; 17: 1332-1333
Year: 2001


Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once daily inhalation as a fixed-dose combination in healthy subjects
Source: International Congress 2019 – Clinical studies of asthma treatments
Year: 2019


Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma
Source: Eur Respir J 2014; 43: 773-782
Year: 2014



Formoterol: a new pMDI CFC free formulation. Efficacy of the 12µg dosage versus a dry powder inhaler in moderate to severe asthmatic patients
Source: Eur Respir J 2003; 22: Suppl. 45, 284s
Year: 2003

Efficacy and safety of combined mometasone furoate/formoterol 100/10μg twice daily in subjects with asthma inadequately controlled on low-dose inhaled corticosteroids
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010


Comparison of mometasone furoate dry powder inhaler 400 mcg once daily in the evening with fluticasone propionate metered dose inhaler 250 mcg twice daily in asthma patients previously maintained on fluticasone propionate
Source: Eur Respir J 2003; 22: Suppl. 45, 34s
Year: 2003

Beclometasone/formoterol administered via extrafine dry powder inhaler in controlled asthmatic patients: Comparison with pMDI and beclometasone monotherapy
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012


Young children with asthma treated with budesonide inhalation suspension can successfully be transitioned to once-daily budesonide dry powder inhaler
Source: Annual Congress 2007 - Anti-inflammatory therapy for childhood asthma
Year: 2007


Mometasone furoate 400 μg once daily is more efficacious than budesonide 400 μg once daily in improving asthma symptoms in patients with moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 96s
Year: 2001